Strengthening Your Retinal Disease Management Muscles

Program Description

Neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), and diabetic macular edema (DME) are leading causes of visual impairment and blindness. The advent of vascular endothelial growth factor (VEGF) inhibitors, and later anti-VEGF and anti-angiopoietin 2 (Ang-2) bispecific agents, has revolutionized treatment. Treatment decision-making in nAMD, DR, and DME is highly individualized, with the goal of preserving visual acuity, reducing fluid, and minimizing treatment burden as much as possible. In this interactive activity, Dr. Aleksandra Rachitskaya will use text, visuals, and video to review pathophysiology, key clinical trials, real-world data, challenges in daily practice, and monitoring strategies.

Target Audience

This multimedia program addresses identified knowledge and practice gaps among ophthalmologists and retina specialists.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Monitor disease control over time to inform treatment plans and optimize outcomes in patients with DR, DME, or nAMD
2. Incorporate efficacy and safety data of VEGF inhibitor or bispecific agents, biomarkers, and patient characteristics into individualized treatment plans
3. Apply insights from real-world experience to drive improved outcomes for retinal vascular diseases in daily practice

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas Communications designates this enduring for a maximum of 0.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Aleksandra Rachitskaya, MD:

• Consulting Fees (e.g., advisory boards): 4D Molecular Therapeutics, Inc., AbbVie Inc./Allergan, Inc., Alcon Inc., Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Boehringer Ingelheim, Carl Zeiss Meditec AG, EyePoint Pharmaceuticals, Inc., Ethis Inc., Lenz Therapeutics, Inc., Ocular Therapeutix, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd./Genentech, Inc., Samsara Vision, Inc.
• Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Boehringer Ingelheim, Genentech, Inc., Regeneron Pharmaceuticals, Inc.
• Contracted Research: 4D Molecular Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Beacon Therapeutics, DRCR Retina Network, F. Hoffmann-La Roche Ltd./Genentech, Inc., ONL Therapeutics, Inc., ZEISS

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Contact Information

For information about this program, please contact us at info@exchangecme.com.